| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.076 | 0.01 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.075 | 0.01 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.077 | 0.01 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.073 | 0.01 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.076 | 0.02 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |